

MAY 23 2005

LAW OFFICES

KILYK & BOWERSOX, P.L.L.C.

Intellectual Property Law

LUKE A. KILYK* (PA, DC)
LEONARD D. BOWERSOX
JASBIR SINGH
MATTHEW T. GILL
RALPH T. WEBB* (DC, TX, LA)
SUSANNE M. HOPKINS
J. MARK KONIECZNY, Ph.D.* (MA)

53 A East Lee Street
WARRENTON, VA 20186

TEL.: (540) 428-1701
FAC.: (540) 428-1720
(540) 428-1721

FAIRFAX OFFICE
3603-E Chain Bridge Road
Fairfax, Virginia 22030

Email: kilyk@kbpatentlaw.com
Website: <http://www.kbpatentlaw.com>

Of Counsel:

LAWRENCE B. BUGAISKY, Ph.D.* (DC)
WILLIAM CHARLES JAMISON, Ph.D.

*Admitted only to states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: May 23, 2005

TO: Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/523,572
Entitled: METHOD FOR PREPARING PLATELET-RICH PLASMA
Our Ref.: 3190-073

FROM: Luke A. Kilyk, Esq. *LAK*

FAC. TEL. NO.: 1-703-872-9306

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 20

Items Attached: Information Disclosure Statement - 2 pages
Form PTO-1449 - 1 page
2 cited references - 15 pages
Concise Relevance - 1 page

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on May 23, 2005.

Donald S. Prater
Name (Print)

Donald S. Prater / Kim Blum
Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

MAY 23 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on May 23, 2005.

Donald S. Prater
Name (Print)

Donald S. Prater / Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	SUMIDA et al.)	Examiner:	Unassigned
)		
Application No.:	10/523,572)	Group Art Unit:	1615
)		
Filed:	January 28, 2005)	Confirmation No.:	1410
)		
Docket No.:	3190-073)	Customer No.:	33432

For: METHOD FOR PREPARING PLATELET-RICH PLASMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 23, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Supplemental Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Supplemental Information Disclosure statement, then applicants respectfully petition under 37 C.F.R. § 1.97(c) to consider the documents set forth in the Supplemental Information Disclosure Statement.

In lieu of English translations of the non-English documents, the relevance of each document, as provided by the applicant, is attached.

The above information is presented so that the Patent and Trademark Office can, in the first

Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/523,572


instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-073
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: Form PTO-1449 and 2 documents

Sumida et al.
U.S. Patent Application No. 10/523,572

CONCISE RELEVANCE

Garg et al., "Platelet-Rich Plasma to Enhance Bone Augmentation for Dental Implants," *The Nippon Dental Review*, Vol. 62, No. 10, pp. 131-143 (2002):

This reference relates to PRP obtained by a centrifugation method. For example, because activated blood platelets secrete substances that induce migration and differentiation of cells in the early stage of wound healing, a method has been attempted that a patient's own blood is previously concentrated to make blood plasma rich in platelets ("platelet-rich plasma", hereunder sometimes referred to as "PRP") prior to surgery, which are then activated to apply the PRP to an operation area in order to accelerate healing.

Rinshou Kensahou Teiyuu, 31st edition, p. 400 (September 20, 1998):

This reference discusses platelet-rich plasma used for clinical laboratory tests that is obtained by collecting blood from intermediate ante-brachial vein, adding 4.5 mL of the whole blood to each plastic tube including 1.5 mL of a 3.1% w/v sodium citrate solution, mixing by inversion, and then centrifuging at 50 g (500-600 rpm) for 15 minutes at 22 °C to collect the supernatant.

Page 1 of 1

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-073	Application No. 10/523,572
INFORMATION DISCLOSURE STATEMENT	APPLICANT: SUMIDA et al.	
	Filing Date: January 28, 2005	Group Art Unit: 1615

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

ACQUISITION DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Garg et al., "Platelet-Rich Plasma to Enhance Bone Augmentation for Dental Implants," <i>The Nippon Dental Review</i> , Vol. 62, No. 10, pp. 131-143 (2002) (in Japanese)
	Rinshou Kensahou Teyou, 31 st edition, p. 400 (September 20, 1998) (in Japanese)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.